Full text

Turn on search term navigation

© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

Details

Title
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
Author
Ryan, Christine E. 1   VIAFID ORCID Logo  ; Ahn, Inhye E. 1 ; Sekar, Aswin 1 ; Rawstron, Andrew 2 ; Almeida, Julia 3   VIAFID ORCID Logo  ; Martin-Subero, Iñaki 4   VIAFID ORCID Logo  ; Parry, Erin M. 1 ; Alcoceba, Miguel 5 ; Calado, Dinis P. 6 ; Orfao, Alberto 3   VIAFID ORCID Logo  ; Langerak, Anton W. 7   VIAFID ORCID Logo  ; Veelken, Hendrik 8   VIAFID ORCID Logo  ; Langerbeins, Petra 9 ; Stephens, Deborah M. 10 ; Parikh, Sameer A. 11   VIAFID ORCID Logo  ; Niemann, Carsten U. 12   VIAFID ORCID Logo  ; Roulland, Sandrine 13 ; Stamatopoulos, Kostas 14   VIAFID ORCID Logo  ; Slager, Susan L. 15   VIAFID ORCID Logo  ; Shanafelt, Tait 16 ; Ghia, Paolo 17   VIAFID ORCID Logo  ; Okosun, Jessica 18   VIAFID ORCID Logo  ; Davids, Matthew S. 1   VIAFID ORCID Logo 

 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910) 
 Leeds Teaching Hospitals NHS Trust, Leeds, UK (ROR: https://ror.org/00v4dac24) (GRID: grid.415967.8) (ISNI: 0000 0000 9965 1030) 
 Translational and Clinical Research Program, Cancer Research Center (IBMCC; CSIC–University of Salamanca); Cytometry Service (NUCLEUS); Department of Medicine, and ECRIN M3 Consortium, University of Salamanca, Salamanca, Spain (ROR: https://ror.org/02f40zc51) (GRID: grid.11762.33) (ISNI: 0000 0001 2180 1817); Instituto de Investigación Biomédica de Salamanca, and ECRIN M3 Consortium, Salamanca, Spain; and CIBERONC, Institute of Health Carlos III., Madrid, Spain (ROR: https://ror.org/00ca2c886) (GRID: grid.413448.e) (ISNI: 0000 0000 9314 1427) 
 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (ROR: https://ror.org/054vayn55) (GRID: grid.10403.36) (ISNI: 0000000091771775) 
 Instituto de Investigación Biomédica de Salamanca, and ECRIN M3 Consortium, Salamanca, Spain; and CIBERONC, Institute of Health Carlos III., Madrid, Spain (ROR: https://ror.org/00ca2c886) (GRID: grid.413448.e) (ISNI: 0000 0000 9314 1427); Department of Hematology, University Hospital of Salamanca, Salamanca, Spain (ROR: https://ror.org/00nyrjc53) (GRID: grid.425910.b) 
 The Francis Crick Institute, London, UK (ROR: https://ror.org/04tnbqb63) (GRID: grid.451388.3) (ISNI: 0000 0004 1795 1830) 
 Department of Immunology, Laboratory Medical Immunology, Rotterdam, Erasmus MC, the Netherlands (ROR: https://ror.org/018906e22) (GRID: grid.5645.2) (ISNI: 0000 0004 0459 992X) 
 Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands (ROR: https://ror.org/05xvt9f17) (GRID: grid.10419.3d) (ISNI: 0000 0000 8945 2978) 
 Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (ROR: https://ror.org/05mxhda18) (GRID: grid.411097.a) (ISNI: 0000 0000 8852 305X) 
10  University of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC, USA (ROR: https://ror.org/0130frc33) (GRID: grid.10698.36) (ISNI: 0000 0001 2248 3208) 
11  Division of Hematology, Mayo Clinic, Rochester, MN, USA (ROR: https://ror.org/02qp3tb03) (GRID: grid.66875.3a) (ISNI: 0000 0004 0459 167X) 
12  Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (ROR: https://ror.org/05bpbnx46) (GRID: grid.4973.9) (ISNI: 0000 0004 0646 7373) 
13  Aix-Marseille University, CNRS, INSERM, Centre d’Immunologie de Marseille-Luminy, Marseille, France (ROR: https://ror.org/03vyjkj45) (GRID: grid.417850.f) (ISNI: 0000 0004 0639 5277) 
14  Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece (ROR: https://ror.org/03bndpq63) (GRID: grid.423747.1) (ISNI: 0000 0001 2216 5285) 
15  Division of Hematology, Mayo Clinic, Rochester, MN, USA (ROR: https://ror.org/02qp3tb03) (GRID: grid.66875.3a) (ISNI: 0000 0004 0459 167X); Division of Computational Biology, Mayo Clinic, Rochester, MN, USA (ROR: https://ror.org/02qp3tb03) (GRID: grid.66875.3a) (ISNI: 0000 0004 0459 167X) 
16  Stanford University School of Medicine, Stanford, CA, USA (ROR: https://ror.org/00f54p054) (GRID: grid.168010.e) (ISNI: 0000000419368956) 
17  Università Vita-Salute San Raffaele, Milano, Italy (ROR: https://ror.org/01gmqr298) (GRID: grid.15496.3f) (ISNI: 0000 0001 0439 0892); IRCCS Ospedale San Raffaele, Milano, Italy (ROR: https://ror.org/039zxt351) (GRID: grid.18887.3e) (ISNI: 0000 0004 1758 1884) 
18  Barts Cancer Institute, Queen Mary University of London, London, UK (ROR: https://ror.org/026zzn846) (GRID: grid.4868.2) (ISNI: 0000 0001 2171 1133) 
Pages
148
Section
Meeting Report
Publication year
2025
Publication date
Dec 2025
Publisher
Springer Nature B.V.
e-ISSN
20445385
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3244978753
Copyright
© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.